Ikashi Screener(USA)

Merck & Co., Inc.

MRK · CIK 0000310158 · NYSE · Healthcare (Pharmaceutical Preparations)

Overview — Merck & Co., Inc.

Revenue (TTM)
$66.57B
Net Income (TTM)
$3.17B
Total Assets
$129.80B
Total Debt
$53.90B

Pros

  • Strong free cash flow generation
  • Operating cash flow comfortably exceeds reported net income

Cons

  • Thin net profit margin

Chart

No price data yet — run npm run ingest:prices in apps/api.

Revenue & Net Income

RevenueNet Income
025B50B75B100B2016201720182019202020212022202320242025TTM

Peers

Sector: Healthcare. Sector is derived from SEC's SIC code, not GICS. Click a column to sort.

CompanyMarket Cap ▼Revenue (TTM) Net Income (TTM) Net Margin ROE Debt/Equity
JNJ JOHNSON & JOHNSON$660.42B$99.33B$16.09B16.2%19.7%0.44
PFE PFIZER INC$169.02B$63.70B$4.36B6.8%5.1%0.71
ABBV AbbVie Inc.—$64.39B$6.32B9.8%-106.4%—
MRK Merck & Co., Inc.—$66.57B$3.17B4.8%7.6%1.28
MMM 3M CO—$25.25B$3.58B14.2%85.9%3.01

Quarterly results

Line itemSep 22Mar 23Jun 23Sep 23Mar 24Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26
Revenue$14.96B$14.49B$15.04B$15.96B$15.78B$16.11B$16.66B$15.53B$15.81B$17.28B$16.29B$16.61B
Net Income$3.25B$2.83B-$5.97B$4.75B$4.77B$5.46B$3.16B$5.08B$4.43B$5.79B-$4.24B-$1.34B
Operating Cash Flow—$1.34B——$3.09B——$2.50B——$3.92B—

Profit & Loss

Line item2016201720182019202020212022202320242025TTM
Revenue$39.81B$40.12B$42.29B$46.84B$47.99B$48.70B$59.28B$60.12B$64.17B$65.01B$66.57B
Net Income$3.94B$2.42B$6.22B$9.84B$7.08B$13.05B$14.53B$377.00M$17.13B$18.26B$3.17B

Balance Sheet

Line item2016201720182019202020212022202320242025TTM
Total Assets$95.38B$87.87B$82.64B$84.40B$91.59B$105.69B$109.16B$106.67B$117.11B$136.87B$129.80B
Total Liabilities———————————
Total Equity$40.31B$34.57B$26.88B$26.00B$25.40B$38.26B$46.06B$37.63B$46.37B$52.66B$41.98B
Total Debt$24.27B$21.35B$25.10B$26.30B$31.80B$33.10B$30.70B$35.10B$37.10B$49.30B$53.90B
Shares Outstanding2,745,571,0672,696,190,5022,581,220,3082,536,268,7602,530,315,6682,527,733,6062,538,592,4672,532,643,8722,526,036,2402,472,392,0032,467,171,638

Cash Flow

Line item2016201720182019202020212022202320242025TTM
Operating Cash Flow$10.38B$6.45B$10.92B$13.44B$10.25B—$19.09B$13.01B$21.47B$16.47B$17.89B
Capex—————$4.45B$4.39B$3.86B$3.37B$4.11B$3.77B

Ratios

Profitability

Ratio2016201720182019202020212022202320242025TTM
Net margin9.9%6.0%14.7%21.0%14.8%26.8%24.5%0.6%26.7%28.1%4.8%
Return on equity9.8%7.0%23.1%37.9%27.9%34.1%31.5%1.0%36.9%34.7%7.6%
Return on assets4.1%2.8%7.5%11.7%7.7%12.3%13.3%0.4%14.6%13.3%2.4%
Return on capital employed (ROCE)———————————
Debt / Equity0.600.620.931.011.250.870.670.930.800.941.28
FCF margin——————24.8%15.2%28.2%19.0%21.2%

Working capital

Ratio2016201720182019202020212022202320242025TTM
Debtor days64d63d61d53d60d69d58d63d58d66d69d
Inventory days127d144d147d155d149d159d124d144d147d148d126d
Payable days73d88d90d97d108d123d89d89d98d98d78d
Cash conversion cycle118d119d118d111d100d105d93d118d107d116d117d
Working capital days123d56d32d41d3d48d71d39d59d85d49d

Investors

US filings have no equivalent to India's Promoter/FII/DII shareholding-pattern disclosure. Shown below are the closest real US sources: Form 4 insider transactions and Form 13F institutional holders (matched by issuer name, not CUSIP — a few companies, especially ones that changed their legal name, may be incomplete).

Institutional Holders

No data yet — run npm run ingest:institutions in apps/api.

Insider Trades

PersonRelationshipDateTypeSharesPrice
Guindo ChirfiEVP, Access, Policy & Comms8/13/2026Sale10,000$135.00
Zachary JenniferEVP, General Counsel8/12/2026Option exercise41,494$117.89
Zachary JenniferEVP, General Counsel8/12/2026Option exercise13,433$84.71
Zachary JenniferEVP, General Counsel8/12/2026Sale80,315$133.46
DeLuca Richard R.EVP&Pres, Merck Animal Heallth8/12/2026Sale11,099$131.61
DeLuca Richard R.EVP&Pres, Merck Animal Heallth8/12/2026Sale600$132.04
DeLuca Richard R.EVP&Pres, Merck Animal Heallth8/11/2026Sale7,410$131.33
DeLuca Richard R.EVP&Pres, Merck Animal Heallth8/11/2026Sale5,427$132.35
DeLuca Richard R.EVP&Pres, Merck Animal Heallth8/10/2026Sale20,784$130.43
DeLuca Richard R.EVP&Pres, Merck Animal Heallth8/6/2026Sale805$131.02
DeLuca Richard R.EVP&Pres, Merck Animal Heallth8/6/2026Sale4,945$130.23
DeLuca Richard R.EVP&Pres, Merck Animal Heallth8/6/2026Sale300$131.02
Guindo ChirfiEVP, Access, Policy & Comms8/6/2026Sale15,000$131.00
Maraldo David R.EVP & Pres. MMD8/5/2026Option exercise6,311$73.73
Maraldo David R.EVP & Pres. MMD8/5/2026Sale6,311$128.72
Maraldo David R.EVP & Pres. MMD8/5/2026Option exercise9,709$87.10
Maraldo David R.EVP & Pres. MMD8/5/2026Sale9,709$128.72
Maraldo David R.EVP & Pres. MMD8/5/2026Option exercise2,686$84.71
Maraldo David R.EVP & Pres. MMD8/5/2026Sale2,686$128.72
Williams David MichaelEVP,Chief Info&Digital Officer8/5/2026Option exercise4,600$77.62
Williams David MichaelEVP,Chief Info&Digital Officer8/5/2026Sale4,600$128.77
Williams David MichaelEVP,Chief Info&Digital Officer8/5/2026Option exercise13,542$75.36
Williams David MichaelEVP,Chief Info&Digital Officer8/5/2026Sale13,542$128.77
Williams David MichaelEVP,Chief Info&Digital Officer8/5/2026Option exercise34,705$73.73
Williams David MichaelEVP,Chief Info&Digital Officer8/5/2026Sale34,705$128.77

Documents